News

The therapy would be the first capsid inhibitor and the only HIV treatment option administered every 6 months.

The Food and Drug Administration (FDA) said the company is concerned about cyclospora contamination on the company’s Dole Fresh Blueberries brand.

A discussion about the Association for Professionals in Infection Control and Epidemiology with CEO Devin Jopp.

Screening and isolation protocols were shown to reduce the risk of transmission.

AFHs reported concerns such as staff coming to work sick and lack of PPE.

IPs experienced PPE shortages, high levels of stress and emotional exhaustion.

A study looked at the prevalence of Metallo-B-lactamase (MBLs) producing A. baumannii isolates in one hospital setting.

Staff trainings on prevention practices were found to be common by inconsistent.

This event will be a free, virtual event in July with expert speakers and survivors.

The newly approved therapy will use the brand name, Brexafemme, and is a one-day, novel, oral treatment for vaginal yeast infection.

A significant decrease in the rate of VAP occurred during the study period.

Post-intervention saw 55% of patients receive overall guideline-concordant antibiotics.

Nonspecific, nondolent symptoms make this disease difficult to diagnose.

The Sinovac developed vaccine generated antibodies against SARS-CoV-2 in a phase 1/2 trial.

Sensors provided data for more hand washing opportunities for healthcare workers and affected related behaviors.

The CAD demonstrated excellent sustained antiviral activity against the test pathogen.

Average annual discharges were significantly higher in participating hospitals.

Communal gathering areas were found to be a major source of exposure.

Investigators apply guidelines into practical management strategies.

During the pandemic, one regional health system looked at the age distribution of the virus and hospitalization and mortality rates.

AstraZeneca’s COVID-19 vaccine was safe and immunogenic for people with HIV who are well-controlled on antiretroviral therapy, a study has shown.

New model uses syndromic surveillance to predict admissions related to SARS-CoV-2.

The therapy is known to exhibit antiviral properties and reduce SARS-CoV-2 replication in laboratory studies.

Seqirus is seeking reactogenicity and immunogenicity outcomes between its influenza vaccines and available mRNA vaccines for COVID-19.

Plus: how could the COVID-19 testing market boom improve public flu awareness?

Recommendations based on local pollen levels may help manage infection risk.

The challenging search for a metric that effectively evaluates an ASP’s direct impact on appropriate antimicrobial use and improved patient outcomes.

As many vaccines are under Emergency Use Authorization (EUA), understanding the incidence rates of adverse events is critical to providing education and awareness, while working to increase distribution.